Anlon Healthcare Limited has successfully completed its strategic acquisition of Apiqo Organics Private Limited, marking a significant milestone in the company's expansion strategy. The pharmaceutical company announced the completion of acquiring a 67.48% equity stake in the target company on January 9, 2026.

Acquisition Details

The acquisition was executed in accordance with the Share Purchase Agreement (SPA) dated December 2, 2025, which was previously disclosed to the stock exchanges. Following the completion of this transaction, Apiqo Organics Private Limited has become a subsidiary of Anlon Healthcare Limited.

Regulatory Compliance

The investment and acquisition transaction has been structured in full compliance with applicable regulatory requirements. The company confirmed that the acquisition adheres to Section 179(3)(e) & (j) and all other applicable provisions of the Companies Act, 2013.

The disclosure was made pursuant to Regulation 30(7) read with Para A of Part A of Schedule III of the SEBI Listing Regulations. This follows the company's earlier intimation dated December 2, 2025, regarding the execution of the Share Purchase Agreement.

Corporate Structure Impact

With the completion of this acquisition, Anlon Healthcare has expanded its corporate structure through the addition of Apiqo Organics as a subsidiary. The target company was formerly known as M/s Apple Life Science, operating as a partnership firm before its transformation into a private limited company.

The transaction details, as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, were previously provided in the December 2, 2025 disclosure to ensure complete regulatory transparency.

Management Authorization

The acquisition completion was formally communicated to both BSE Limited and The National Stock Exchange of India Ltd by Managing Director Punitkumar Rasadia, who digitally signed the disclosure document on January 9, 2026. The communication ensures that all stakeholders and regulatory bodies are informed of this significant corporate development in accordance with listing obligations.

Anlon Healthcare Limited has successfully secured shareholder approval for its strategic shift in IPO fund utilization, with an overwhelming majority voting in favor of reallocating ₹2,332.69 lakhs from capital expenditure to strategic acquisitions. The postal ballot concluded on January 7, 2026, marking a significant milestone in the company's growth strategy.

Voting Results Overview

The postal ballot results demonstrate strong shareholder confidence in the company's strategic direction:

Strategic Fund Reallocation Details

The approved resolution allows Anlon Healthcare to redirect funds originally planned for greenfield expansion towards strategic acquisitions:

Postal Ballot Process

The voting process was conducted entirely through electronic means, with Mr. Keyur Ghelani of M/s. K. P. Ghelani and Associates serving as the scrutinizer. The e-voting facility was provided by Kfin Technologies Limited, ensuring transparency and compliance with regulatory requirements.

Strategic Benefits

The approved strategy shift from greenfield to brownfield investment offers several advantages:

• Immediate Capacity Addition: Access to validated production lines and established systems
• Time Efficiency: Avoiding longer timelines associated with new facility construction
• Early Revenue Generation: Faster monetization of acquired assets
• Operational Synergies: Leveraging existing regulatory approvals and trained workforce

Financial Impact

The reallocation represents a significant portion of the company's IPO proceeds:

With this overwhelming shareholder approval, Anlon Healthcare can now proceed with its planned acquisitions of Bizotic Lifescience Private Limited and Apiqo Organics Private Limited, positioning the company for accelerated growth through strategic inorganic expansion.